Last reviewed · How we verify
IMC-001
At a glance
| Generic name | IMC-001 |
|---|---|
| Also known as | Not confirm yet |
| Sponsor | ImmuneOncia Therapeutics Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study Evaluating the Stability and Efficacy of IMC-001 for Injection on Atherosclerotic Plaques in Patients With ACS. (PHASE2)
- Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study (PHASE1)
- A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type (PHASE2)
- A Study of IMC-001 In Patients With Metastatic Or Locally Advanced TMB-H Solid Tumor (PHASE2)
- Phase II Study of Neoadjuvant Immune Checkpoint Inhibitor in Patients With Resectable Gastrointestinal Cancers (PHASE2)
- IMC001 for Clinical Research on Advanced Digestive System Malignancies (PHASE1)
- A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies (PHASE2)
- Dose-escalation Study of IMC-001 in Subject With Metastatic or Locally-advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IMC-001 CI brief — competitive landscape report
- IMC-001 updates RSS · CI watch RSS
- ImmuneOncia Therapeutics Inc. portfolio CI